Skip to main content

Table 3 Cost-effectiveness results of different PMTCT strategies under scenario analyses on a simulated birth cohort of 10,000 live singleton infants

From: Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa

Strategy Number of infant HBV infectionsa (95% CI) Cost of deploying the intervention for the whole population (n = 10,000) in USD (95% CI) Incremental cost per infection avoided (USD)
Scenario analysis (i): POCT testing
 S1 45 (28–119) 0  
 S2b 22 (14–73) 23,401 (23,330 – 24,243) 1017 (compared to strategy S1)
 S3b 28 (19–78) 23,979 (23,882 – 25,937) Dominatedc (by strategy S2)
Scenario analysis (ii): Universal birth dose vaccination
 S1 45 (28–123) 0
 S2d 15 (11–82) 94,571 (94,489 - 95,503) 3152 (compared to strategy S1)
 S3d 24 (17–84) 95, 097 (94,981 – 97,291) Dominatedc (by strategy S2)
Scenario analysis (iii): TDF resistance
 S1 45 (29–119) 0
 S2d 21 (14–71) 94,571 (94,496 – 95,515) 3940 (compared to strategy S1)
 S3d 28 (18–79) 95,097 (94,980 – 97,252) Dominatedc (by strategy S2)
  1. a World Health Organisation (WHO) criteria for HBV elimination states an aim of 90% reduction in new chronic infection [1]
  2. b Price of TDF estimated at $2.42/month for strategies S2 and S3 when using POCT
  3. c S3 is dominated due to both higher costs and higher infections compared to S2
  4. d Price of TDF estimated at $2.48/month for strategies S2 and S3 [30]
  5. CI = confidence interval